Jonathan Huang, DO
Gastroenterology · Rochester, NYNPI 1487711743
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.4%), food and beverage and education — rather than concentrated in one kind of arrangement. Bristol Myers Squibb accounts for 60.9% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for gastroenterology clinicians in NY, where the typical reported total is $1,827.
Across 6 payments — averaging $218.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$799
- Dentsply Sirona Inc$513
Across 189 payments — averaging $3343.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$272K
- Gilead$241K
- Intercept Pharma Europe Ltd.$55K
- Bristol Myers Squibb$51K
- AbbVie$13K
What the payments were for
- Travel & lodging$60946%
- Food & beverage$52740%
- Education$17613%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 3 | $799 |
| Dentsply Sirona Inc | 3 | $513 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CC-90001$799
How this compares
$1,312 in reported general payments places this provider in the 40th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 20 | $167,580 |
| Ursodiol | 20 | $1,405 |
| Spironolactone | 45 | $411 |
| Furosemide | 14 | $47 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Rochester
- Vivek KaulRochester$226K
- Jeffrey GoldsteinRochester$214K
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.